$YCBDJul 7, 2026, 12:30 PMAI processed
cbdMD (YCBD) self-affirms GRAS for its broad‐spectrum CBD, sets 200 mg/day limit
AI Summary
CbdMD announced completion of a self-affirmed GRAS determination supporting safe consumption of up to 200 mg/day of cannabidiol from its proprietary broad‐spectrum hemp extract, based on an independent toxicology panel review of a company-assembled dossier of peer‐reviewed preclinical and clinical studies. The company says the determination provides a science-backed daily intake ceiling to support product positioning across consumer and healthcare channels and aligns with recent CMS and FDA signals that could expand physician-guided access to tested oral CBD products.
Positives
- Self-affirmed GRAS supports a clear daily intake ceiling of up to 200 mg CBD for healthy adults
- Determination based on a dossier of peer‑reviewed studies including preclinical toxicology and a double-blind tolerability trial in healthy adults
- Gives cbdMD a science-backed claim that may help place products in healthcare-oriented channels amid recent CMS/FDA policy signals
Negatives
- GRAS is self-affirmed by the company (not an FDA approval) despite review by an independent panel
- Safety studies cited were sponsored by cbdMD, which can raise questions about independence of the evidence
- Federal and state regulation of hemp-derived THC/CBD is still evolving and this determination doesn't guarantee regulatory or commercial outcomes